Key Details of the Approval
- Reference: Letter No. SMIORE / SEC / 2026-27 / 47
- Board Meeting Details: 387th meeting held on 17 September 2026, commencing at 4:30 PM and concluding at 5:00 PM
- Approval: Incorporation of a Wholly Owned Subsidiary under the name 'Royal Sandur MedTech Private Limited', subject to necessary approvals
Details of the Proposed Subsidiary (As per Annexure A)
- Name of Entity: Royal Sandur MedTech Private Limited
- Incorporation Status: The company is yet to be incorporated
- Country of Incorporation: India
- Holding Company: The Sandur Manganese & Iron Ores Limited
- Relation: Wholly Owned Subsidiary
- Industry: Medical devices and consumables manufacturing
Business Scope of the Subsidiary
Royal Sandur MedTech Private Limited will be incorporated to carry on the business of medical devices and consumables manufacturing including but not limited to manufacturing, processing, assembling, marketing and distribution of medical devices, surgical products, diagnostic products and healthcare consumables.
Regulatory and Financial Details
- Governmental/Regulatory Approvals: Will be incorporated subject to applicable laws and regulatory approvals, as required
- Nature of Consideration: Subscription of equity shares in cash
- Cost of Subscription: 10,00,000 equity shares of ₹10 each aggregating to ₹1,00,00,000/-
- Shareholding Percentage: 100%
Additional Context
This disclosure references an earlier communication (Letter No. SMIORE / SEC / 2026-27 / 19 dated 9 July 2026) pertaining to the company's venturing into new lines of business, indicating this subsidiary formation is part of that strategic initiative.